Targeting Aging and Promoting Longevity with Exogenous Nucleotides (TALENTs)

Peking University

Status

Completed

Conditions

Aging

Treatments

Dietary Supplement: placebo

Dietary Supplement: dietary nucleotides

Study type

Interventional

Funder types

Other

Identifiers

NCT05243108

TALENTs

Details and patient eligibility

About

To investigate the effects of dietary nucleotides (NTs) as an anti-aging supplement, a clinical trial is carried as a randomized, double-blind, parallel design, placebo-controlled. A total of 120 subjects will be enrolled in the study, and they shall be randomly distributed between the two arms, NTs-treated, and placebo-control. They would be given several measurements, including physical examination, questionnaire survey, clinical and aging-related biomarkers tests at 0 (baseline), 2, and 4 months during the RCT.

Full description

To explore the anti-aging effects of NTs and the regulation of aging-related diseases, this study plans to recruit 120 people as subjects and conduct randomized controlled trials with NTs as an intervention for 4 months. Based on computer-generated random numbers, participants who meet the inclusion criteria are randomly assigned equally to two groups: placebo control and nucleotide intervention groups. In this study, the specific nucleotide composition is 5'-AMP、5'-CMP、5'-GMPNa2、5'-UMPNa2 prepared according to the ratio of 16:41:19:24, which is consistent with the ratio in breast milk and meets the requirements of national infant formula addition and special medical food formula. The dose of 1.2 g/day used is currently approved as the ingredient dose of nucleotides in conventional commercially available health food products. At the 0、2 and 4 months of the study, comprehensive geriatric health assessment, aging biomarker testing and biological sample collection will be conducted. Among them, the comprehensive evaluation of elderly health status is carried out by physical examination and questionnaire survey, including physical health, physiological function, quality of life, cognitive function, psychosocial health, and other aspects of information. The physical examination involves both physical assessment and functional assessment, including body composition, neck circumference, waist circumference, hip circumference, middle arm circumference, calf circumference, BMR, grip strength, six-minute walk, intima-media thickness, subcutaneous AGEs, and spirometry. The scale includes health status, nutritional status, cognitive status, physical activity, and dietary status. Blood samples were used to detect the safety and senescence-related indicators of the subjects. The index system covers four modules and seventeen dimensions, including blood routine, blood biochemistry, inflammatory factors, immune antibodies, T lymphocyte subtypes, oxidative stress level, cancer markers, leukocyte telomere length, DNA methylation, γ-H2A. Blood samples are sequenced simultaneously for gene and transcriptome sequencing. Fecal samples are collected for metagenomic sequencing of intestinal flora.

Enrollment

122 patients

Sex

All

Ages

60 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male/females of 60 to 70 years of age
No serious physical or mental illness
Able to provide written Informed Consent
Able to follow verbal and written study directions
Must not be taking or be willing to take any supplements containing any form of nucleotides for one year prior to baseline and for the duration of the study.
Able to maintain consistent diet and lifestyle habits throughout the study
Willing to consume assigned supplement (NTs or placebo) for 4 months

Exclusion criteria

Participants on the current use of prescription or over-the-counter nucleotides
Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator
Documented presence of atherosclerotic disease and/or cardiopulmonary disease
History of drug or alcohol abuse
History of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participant's ability to comply with study requirements
Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant.
Currently, or within the past 30 days, enrolled in a different clinical investigation
Inability to provide a venous blood sample
Unable or unwilling to provide written informed consent for participation in the study